[TAF15::ZNF384融合基因急性B淋巴细胞白血病的临床特点]。

Q3 Medicine
Z Wang, X L Ma, F Wang, Y Zhang, L L Yuan, P X Cao, Y C Tan, X Chen, J Q Chen, J C Fang, H X Liu
{"title":"[TAF15::ZNF384融合基因急性B淋巴细胞白血病的临床特点]。","authors":"Z Wang, X L Ma, F Wang, Y Zhang, L L Yuan, P X Cao, Y C Tan, X Chen, J Q Chen, J C Fang, H X Liu","doi":"10.3760/cma.j.cn112137-20250220-00407","DOIUrl":null,"url":null,"abstract":"<p><p>A retrospective analysis was conducted on the clinical data of acute B lymphoblastic leukemia (B-ALL) patients with TAF15::ZNF384 fusion gene positive at Hebei Yanda Ludaopei Hospital from December 2018 to February 2022. The patients were followed up until December 2024 to analyze their clinical characteristics and outcomes. A total of 6 patients were included, including 4 males and 2 females, aged 16 to 47 years. The follow-up period ranged from 10 days to 65 months. All 6 patients sought medical attention due to incomplete remission (CR) after treatment at an external hospital or short-term recurrence after CR. Five of the 6 patients presented with chromosomal abnormalities at initial diagnosis, including 4 with t(12;17) (p13;q12) chromosomal translocation. Immunophenotyping showed the B lymphatic system markers CD19, CD22, and cytoplasmic CD79a were positive in all cases, accompanied by positive myeloid markers such as CD33 or CD31. Four patients showd positive expression of the lymphoid maker CD10. Among the 6 patients, 4 patients achieved CR after receiving chimeric antigen receptor T-cell (CAR-T) therapy, and maintained CR after bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT). B-ALL patients harboring the TAF15::ZNF384 fusion gene often present with complex chromosomal abnormalities at the initial diagnosis and the immunophenotype is often characterized by B lymphatic system with positive myeloid markers. CAR-T immunotherapy followed by allo-HSCT may offer a promising approach to improving their prognosis.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"105 33","pages":"2883-2886"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Clinical features of acute B lymphoblastic leukemia with TAF15::ZNF384 fusion gene].\",\"authors\":\"Z Wang, X L Ma, F Wang, Y Zhang, L L Yuan, P X Cao, Y C Tan, X Chen, J Q Chen, J C Fang, H X Liu\",\"doi\":\"10.3760/cma.j.cn112137-20250220-00407\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A retrospective analysis was conducted on the clinical data of acute B lymphoblastic leukemia (B-ALL) patients with TAF15::ZNF384 fusion gene positive at Hebei Yanda Ludaopei Hospital from December 2018 to February 2022. The patients were followed up until December 2024 to analyze their clinical characteristics and outcomes. A total of 6 patients were included, including 4 males and 2 females, aged 16 to 47 years. The follow-up period ranged from 10 days to 65 months. All 6 patients sought medical attention due to incomplete remission (CR) after treatment at an external hospital or short-term recurrence after CR. Five of the 6 patients presented with chromosomal abnormalities at initial diagnosis, including 4 with t(12;17) (p13;q12) chromosomal translocation. Immunophenotyping showed the B lymphatic system markers CD19, CD22, and cytoplasmic CD79a were positive in all cases, accompanied by positive myeloid markers such as CD33 or CD31. Four patients showd positive expression of the lymphoid maker CD10. Among the 6 patients, 4 patients achieved CR after receiving chimeric antigen receptor T-cell (CAR-T) therapy, and maintained CR after bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT). B-ALL patients harboring the TAF15::ZNF384 fusion gene often present with complex chromosomal abnormalities at the initial diagnosis and the immunophenotype is often characterized by B lymphatic system with positive myeloid markers. CAR-T immunotherapy followed by allo-HSCT may offer a promising approach to improving their prognosis.</p>\",\"PeriodicalId\":24023,\"journal\":{\"name\":\"Zhonghua yi xue za zhi\",\"volume\":\"105 33\",\"pages\":\"2883-2886\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhonghua yi xue za zhi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn112137-20250220-00407\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua yi xue za zhi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112137-20250220-00407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

回顾性分析2018年12月至2022年2月河北省雁达路道陂医院TAF15::ZNF384融合基因阳性的急性B淋巴细胞白血病(B- all)患者的临床资料。随访至2024年12月,分析患者的临床特征和预后。共纳入6例患者,男4例,女2例,年龄16 ~ 47岁。随访时间从10天到65个月不等。6例患者均因在外部医院治疗后不完全缓解(CR)或CR后短期复发而就诊。6例患者中5例在初诊时出现染色体异常,其中4例为t(12;17) (p13;q12)染色体易位。免疫表型分析显示,所有病例B淋巴系统标志物CD19、CD22和细胞质CD79a均阳性,并伴有骨髓标志物CD33或CD31阳性。4例患者淋巴细胞制造细胞CD10阳性表达。6例患者中,4例患者在接受CAR-T治疗后达到CR,并在桥接异体造血干细胞移植(alloo - hsct)后维持CR。携带TAF15::ZNF384融合基因的B- all患者在初诊时常表现为复杂的染色体异常,免疫表型常以B淋巴系统伴髓系标志物阳性为特征。CAR-T免疫治疗后进行同种异体造血干细胞移植可能是改善其预后的一种有希望的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Clinical features of acute B lymphoblastic leukemia with TAF15::ZNF384 fusion gene].

A retrospective analysis was conducted on the clinical data of acute B lymphoblastic leukemia (B-ALL) patients with TAF15::ZNF384 fusion gene positive at Hebei Yanda Ludaopei Hospital from December 2018 to February 2022. The patients were followed up until December 2024 to analyze their clinical characteristics and outcomes. A total of 6 patients were included, including 4 males and 2 females, aged 16 to 47 years. The follow-up period ranged from 10 days to 65 months. All 6 patients sought medical attention due to incomplete remission (CR) after treatment at an external hospital or short-term recurrence after CR. Five of the 6 patients presented with chromosomal abnormalities at initial diagnosis, including 4 with t(12;17) (p13;q12) chromosomal translocation. Immunophenotyping showed the B lymphatic system markers CD19, CD22, and cytoplasmic CD79a were positive in all cases, accompanied by positive myeloid markers such as CD33 or CD31. Four patients showd positive expression of the lymphoid maker CD10. Among the 6 patients, 4 patients achieved CR after receiving chimeric antigen receptor T-cell (CAR-T) therapy, and maintained CR after bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT). B-ALL patients harboring the TAF15::ZNF384 fusion gene often present with complex chromosomal abnormalities at the initial diagnosis and the immunophenotype is often characterized by B lymphatic system with positive myeloid markers. CAR-T immunotherapy followed by allo-HSCT may offer a promising approach to improving their prognosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Zhonghua yi xue za zhi
Zhonghua yi xue za zhi Medicine-Medicine (all)
CiteScore
0.80
自引率
0.00%
发文量
400
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信